Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer-Reference-Cited by-同舟云学术

Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer

Published:2022-10-21 Issue:1 Volume:28 Page:89-98
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Schauer Tim^ORCID,Henriksson Anna^ORCID,Strandberg Emelie^ORCID,Lindman Henrik^ORCID,Berntsen Sveinung,Demmelmaier Ingrid,Raastad Truls^ORCID,Nordin Karin^ORCID,Christensen Jesper F.^ORCID

Funder

The Swedish Cancer Society

The Swedish Research Council

The Nordic Cancer Union

The Oncology Department Foundations Reseach Fund in Uppsala

Trygfonden

Lundbeckfonden

Wereld Kanker Onderzoek Fonds

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-022-02255-0.pdf

Reference40 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319(26):1681–1692. https://doi.org/10.1056/NEJM198812293192601

2. Early Breast Cancer Trialists` Collaborative Group (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/S0140-6736(11)61625-5

3. Early Breast Cancer Trialists’ Collaborative Group (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 393(10179):1440–1452. https://doi.org/10.1016/S0140-6736(18)33137-4

4. Wood WC et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330(18):1253–1259. https://doi.org/10.1056/NEJM199405053301801

5. Piccart MJ, Biganzoli L, Di Leo A (2000) The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 36(suppl 1):4–10. https://doi.org/10.1016/S0959-8049(99)00256-7

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line;Journal of Translational Medicine;2024-04-03

2. Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering;Journal of Multidisciplinary Healthcare;2024-03

3. Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary Study;2024-02-09